{
    "nctId": "NCT05471648",
    "briefTitle": "A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers",
    "officialTitle": "Phase 1, Double-Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Trial of EirGenix' Pertuzumab and Perjeta\u00ae (Pertuzumab) Sourced From US and EU Administered to Healthy Male Volunteers",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 135,
    "primaryOutcomeMeasure": "AUC0-inf of pertuzumab",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* aged 18 to 55 years\n* overtly healthy as determined by medical evaluation\n* Body weight of at least 50 kg and not higher than 105 kg at screening\n* BMI above/equal to 18.0 and below/equal to 30.0 kg/m2 at screening\n* Male\n* Agrees to the following during the treatment period and until 3 months after administration:\n* Be and remain abstinent from heterosexual intercourse OR agree to use a male condom and female partners of childbearing potential must use an additional highly effective contraceptive method\n* Abstain from donating sperm.\n* Signed informed consent\n* Valid COVID-19 immunization status as per current regulations\n\nExclusion Criteria:\n\n* History or evidence of any clinically relevant disease, as judged by the investigator\n* Any medical disorder, condition, or history of such that would impair the participant's ability to participate or complete this trial in the opinion of the investigator\n* Pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination, and effects of the IMP will not be normal\n* Known or suspected hypersensitivity to the IMPs (active substances, or excipients of the preparations)\n* Known severe allergies e.g., allergies to more than 3 allergens\n* Relevant diseases within the last 4 weeks before IMP administration\n* Febrile illness within 2 weeks before IMP administration.\n* History of known or suspected malignant tumors\n* Known or suspected disorder of the liver\n* Use of systemic/topical medicines/substances which oppose the trial objectives, or which might influence them within 4 weeks before IMP administration\n* Regular use of therapeutic or recreational drugs or supplements\n* Use of any herbal products or St. John's wort from 4 weeks before IMP administration\n* Prior treatment with pertuzumab\n* Smoking\n* History of alcohol or drug abuse\n* Regular daily consumption of more than 500 mL of usual beer or the equivalent quantity of approximately 20 g of alcohol in another form\n* Intake of alcohol containing food and beverages from 48 h prior to admission to the ward\n* Regular daily consumption of more than 1 L of methylxanthine-containing beverages\n* Excluded physical therapies that might alter the PK or safety results of the trial from 7 days before IMP administration until follow-up\n* Strenuous physical exercise or sauna visit with 72 h before admission to the ward\n* Donation of more than 100 mL of whole blood or plasma within 4 weeks or approximately 500 mL whole blood within 3 months before IMP administration\n* Plasmapheresis within 3 months before IMP administration\n* Previous or concomitant participation in another clinical trial with IMP(s)\n* Clinically relevant findings in the ECG\n* LVEF below 55%\n* Systolic blood pressure below 100 mmHg or above 140 mmHg\n* Diastolic blood pressure below 50 mmHg or above 90 mmHg\n* Heart rate below 50 beats/ min or above 90 beats/min\n* Clinically relevant findings in the physical examination that may affect the objectives of the trial, or the safety of the participant\n* Poor venous access\n* Clinically relevant deviations of the screened safety laboratory parameters\n* Alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma glutamyl transpeptidase, or total bilirubin above 1.2 upper limit of normal\n* Thyroid disorders as evidenced by assessment of thyroid stimulating hormone (TSH) level outside the normal reference range\n* Positive results for hepatitis B virus surface antigen, hepatitis C virus antibodies, human immune deficiency virus antibodies, and human immune deficiency virus antigen\n* Positive urine drug test\n* Positive alcohol test\n* Positive cotinine test\n* Any criteria which, in the opinion of the investigator, preclude participation for scientific reasons, for reasons of compliance, or for reasons of the participant's safety\n* Close affiliation with the investigational site\n* Vulnerable participants who are e.g., institutionalized due to regulatory or juridical order dependent on sponsor, site, or investigator or not able to consent, respectively.\n* History of COVID-19 within 2 months prior to screening\n* Long COVID-19 syndrome or other clinically relevant COVID-19 related symptoms or sequelae\n* Positive SARS-CoV-2 viral ribonucleic acid (RNA) test at admission\n* No SARS-CoV-2 vaccinations should be booked within 14 days before IMP administration and until last trial visit.",
    "sex": "MALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}